Alpine Immune Sciences Inc (ALPN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
R. Michael Carruthers
Employees:
48
201 ELLIOTT AVE. WEST, SUITE 230, SEATTLE, WA 98119
206-788-4545

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO.

Data derived from most recent annual or quarterly report
Market Cap 263.562 Million Shares Outstanding30.294 Million Avg 30-day Volume 151.07 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.46
Price to Revenue8.0164 Debt to Equity0.0594 EBITDA-45.265 Million
Price to Book Value2.3521 Operating Margin-138.2633 Enterprise Value59.54 Million
Current Ratio2.583 EPS Growth-0.195 Quick Ratio2.523
1 Yr BETA 1.4308 52-week High/Low 14.4 / 6.0 Profit Margin-139.4148
Operating Cash Flow Growth-74.0749 Altman Z-Score0.3719 Free Cash Flow to Firm 12.117 Million
Earnings Report2022-08-09
View SEC Filings from ALPN instead.

View recent insider trading info

Funds Holding ALPN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALPN BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-01:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
  • 8-K: filed on 2021-10-13:
    Item 8.01: Other Events
  • 8-K: filed on 2021-09-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FRAZIER LIFE SCIENCES VIII, L.P.

    FHM LIFE SCIENCES VIII, L.P.

    FHM LIFE SCIENCES VIII, L.L.C.

    HERON PATRICK J

    TOPPER JAMES N

    • Director
    • 10% Owner
    1,484,115 2022-02-11 3

    GOLD MITCHELL EXECUTIVE CHAIRMAN AND CEO

    • Officer
    • Director
    • 10% Owner
    215,000 2022-01-04 3

    RICKEY JAMES PAUL SENIOR VP AND CFO

    • Officer
    112,500 2022-01-04 2

    PENG STANFORD L SEE REMARKS

    • Officer
    215,000 2022-01-04 1

    CONWAY ROBERT E

    • Director
    10,000 2022-01-03 4

    TOPPER JAMES N

    • Director
    • 10% Owner
    10,000 2022-01-03 3

    THOMPSON PETER A.

    • Director
    • 10% Owner
    10,000 2022-01-03 2

    VENKATESAN JAY

    • Director
    • 10% Owner
    10,000 2022-01-03 2

    PEETZ CHRISTOPHER

    • Director
    10,000 2022-01-03 3

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    ORBIMED GENESIS GP LLC

    • Director
    • 10% Owner
    4,081,592 2021-09-17 1

    CUI XIANGMIN

    • Director
    • 10% Owner
    4,708,288 2021-09-17 1

    ALPINE IMMUNOSCIENCES, L.P.

    ALPINE BIOVENTURES, GP, LLC

    • 10% Owner
    2,600,980 2021-09-17 1

    DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P.

    DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC

    • 10% Owner
    4,708,288 2021-09-17 1

    GOLDBERG ZELANNA CHIEF MEDICAL OFFICER

    • Officer
    0 2021-06-01 0

    HERNDAY NATASHA

    • Director
    0 2021-01-04 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • Director
    • 10% Owner
    3,070,955 2020-12-28 1

    SEKHRI PAUL J

    • Director
    0 2020-01-02 0

    TIGER MANAGEMENT L.L.C.

    • 10% Owner
    No longer subject to file 2019-02-08 0

    LITTON MARK JAMES SEE REMARKS

    • Officer
    0 2019-02-06 0

    FRAZIER LIFE SCIENCES VIII, L.P.

    FHM LIFE SCIENCES VIII, L.P.

    FHM LIFE SCIENCES VIII, L.L.C.

    HERON PATRICK J

    • 10% Owner
    2,716,701 2019-01-18 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    ISALY SAMUEL D

    • Director
    0 2017-07-24 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    2,028,158 2017-06-20 0

    TROHA JANICE EXEC VICE PRESIDENT / COO

    • Officer
    10,000 2017-05-05 0

    CARRUTHERS R MICHAEL INTERIM PRESIDENT / CFO

    • Officer
    0 2017-01-12 0

    RODMAN DAVID MALCOM EXEC VICE PRESIDENT AND CMO

    • Officer
    11,368 2017-01-03 0

    SMITH CYNTHIA

    • Director
    0 2016-11-01 0

    FLYNN JAMES E

    DEERFIELD MANAGEMENT CO

    • Director
    • 10% Owner
    0 2016-09-12 0

    MOORE JOHN R

    • Director
    0 2016-09-12 0

    FURST HOWARD P.

    • Director
    0 2016-09-12 0

    LOH EVAN

    • Director
    0 2016-09-12 0

    CONGLETON JON PRESIDENT AND CEO

    • Officer
    • Director
    0 2016-09-12 0

    LEFF JONATHAN S

    • Director
    0 2015-09-11 0

    SHOEMAKER STEVEN VP CLINICAL R&D

    • Officer
    0 2015-09-11 0

    GABRIEL SHERIF VICE PRESIDENT RESEARCH

    • Officer
    0 2015-09-11 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD PRIVATE DESIGN FUND L P

    DEERFIELD PRIVATE DESIGN FUND II, L.P.

    DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P.

    DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    3,732,412 2015-06-23 0

    ROCK SPRINGS CAPITAL MANAGEMENT LP

    • 10% Owner
    No longer subject to file 2015-06-22 0

    HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

    • 10% Owner
    No longer subject to file 2015-06-22 0

    JENNISON GLOBAL HEALTHCARE MASTER FUND, LTD.

    • 10% Owner
    No longer subject to file 2015-06-22 0

    ESTATE OF ARNOLD H. SNIDER, III

    • 10% Owner
    1,557,228 2015-06-22 0

    HAWKES BAY MASTER INVESTORS (CAYMAN) L.P.

    • 10% Owner
    No longer subject to file 2015-06-19 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD PRIVATE DESIGN FUND L P

    DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P.

    DEERFIELD PRIVATE DESIGN FUND II, L.P.

    DEERFIELD PRIVATE DESIGN INTERNATIONAL II, LTD.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    404,022 2015-06-16 0

    TIGER PARTNERS LP

    TIGER PARTNERS GP, LLC

    • 10% Owner
    650,915 2015-06-16 0

    PATTISON RONALD L.

    • Director
    501,828 2011-03-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 22:15:03 UTC -1.709 3.279 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 21:45:03 UTC -1.709 3.279 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 21:15:04 UTC -1.709 3.279 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 20:45:03 UTC -2.1138 3.6838 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 20:15:03 UTC -2.1138 3.6838 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 19:45:03 UTC -2.1138 3.6838 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 19:15:03 UTC -2.1138 3.6838 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 18:45:03 UTC -1.8548 3.4248 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 18:15:04 UTC -1.8548 3.4248 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 17:45:03 UTC -1.8548 3.4248 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 17:15:03 UTC -1.8548 3.4248 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 16:45:03 UTC -1.8453 3.4153 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 16:15:03 UTC -1.8453 3.4153 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 15:45:03 UTC -1.8453 3.4153 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 15:15:03 UTC -1.8453 3.4153 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 14:45:03 UTC -1.5682 3.1382 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 14:15:03 UTC -1.5682 3.1382 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 13:45:03 UTC -1.5682 3.1382 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 13:15:03 UTC -1.5682 3.1382 100000
    ALPINE IMMUNE SCIENCES INC ALPN 2022-06-24 12:45:03 UTC -1.5682 3.1382 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments